Fig. 1. Therapeutic antitumor effect of Annexin A5 protein administration.

C57BL/6 mice (10 per group) were injected with 2 × 10⁵ TC-1 cells/mouse subcutaneously on day 0. Mice were then treated intraperitoneally with 5 mg/kg Cisplatin on days 12 and 15, intravenously with 200jig/mice of Annexin A5 proteins on days 13, 14, 16, and 17, and/or intratumorally with 20jig/mice of E7 long peptide on days 13 and 16. The treatment groups are as follows: opened triangle - PBS only; opened sphere—E7 long peptide only; opened circle—Annexin A5 only; opened square—E7 long peptide and Annexin A5; closed triangle—cisplatin only; closed circle—cisplatin and E7 long peptide; closed sphere—cisplatin and Annexin A5; closed square—cisplatin, E7 long peptide, and Annexin A5. a Schematic diagram. b Line graph depicting TC-1 tumor growth in different treatment groups over time (n = 10). P-values were determined by one-way ANOVA and Turkey’s test. c Kaplan–Meier survival analysis of TC-1 tumor-bearing mice in different treatment groups and the overall P-value was calculated by the log-rank test (n = 10). d, e On days 18 and 23, tumor tissues and spleens of TC-1 tumor-bearing mice in different treatment groups were harvested and analyzed for CD8+IFN-γ+ T cells by flow cytometry analysis, respectively. d Representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+ T cells in splenocytes of TC-1 tumor-bearing mice in different treatment groups. e Representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+tumor-infiltrating T cells in TC-1 tumor-bearing mice in different treatment groups. The error bars indicate mean ± SD. P-values were analyzed by Student’s t test (n = 3). The results are representative of one of three independent experiments. Source data are provided as a Source Data file.